Coming 2026
Klotho
Named for one of the Greek goddesses of fate, Klotho is a highly prized life-extension gene therapy known for its broad health and cognition benefits. Our Proof of Concept Trial on Klotho is planned for summer 2025.
*Minicircle is a gene therapy platform, not a medical provider. All therapies are investigational, have not been reviewed by the FDA, and are administered by licensed clinicians at independent international partner clinics operating under regulatory frameworks outside the United States.
Klotho improves cognition via enhanced hippocampal synaptic plasticity, improved GRIN2B (NMDAR) signaling, and decreased inflammation and neurotoxicity.
Klotho promotes longevity by improving phosphate and calcium homeostasis, activating FOXO3A (a key regulator of cellular stress response and other longevity benefits), and decreasing cellular senescence.
Klotho’s benefits have been demonstrated repeatedly in mice, nonhuman primates, and humans.
Minicircle’s Klotho Gene Therapy is administered via subcutaneous fat injection.
Minicircle’s Klotho Gene Therapy is temporary as it does not integrate with your chromosomes. Treatment effects typically last for approximately one year, though individual experiences may vary.
Anticipated benefits of Klotho Gene Therapy.
How it works.
Klotho is launching soon.
Contact a clinic.
Get started by contacting one of our partner clinics to make an appointment.
Complete testing.
Your clinician will work with you to complete necessary testing before treatment.
Travel to your clinic.
Depending on where you live, you may need to make travel arrangements ahead of your appointment.
Receive therapy.
Our therapies are administered via injection — no surgery, no downtime.
Stay in touch.
Share your experience and connect with others. Our team is available to answer any questions you have along the way.
Re-administer treatment.
People typically re-up their Minicircle treatment at approx. 12 months when effects wear off.
Join the waitlist.
Be among the first to receive Klotho gene therapy when it’s available.
FAQs
Plasmid gene therapy delivers genetic instructions to your cells, enabling them to produce therapeutic proteins internally. Rather than frequent injections of an externally manufactured protein, Minicircle plasmids (circular DNA molecules) prompt the body’s own cells to synthesize the proteins. While results may vary, a single injection of plasmid can support protein production for an entire year, depending on the individual’s unique biochemistry. Learn more.
Minicircle’s therapy uses a single subcutaneous injection to deliver the therapeutic plasmid.
- The plasmid enters the nucleus but does not integrate into the genome.
- The cell produces the encoded protein (e.g. follistatin (FST)), which circulates in the bloodstream.
- The therapeutic effect depends on the specific protein and the individual’s response. For example, FST inhibits myostatin and activin in order to increase lean mass.
Klotho is a protein associated with cognitive function, cellular stress response, and longevity. It may support improved learning and memory via synaptic plasticity, reduced neuroinflammation and toxicity, and longevity pathways through phosphate/calcium balance and FOXO3A activation.
Klotho therapy is currently in development and is expected to launch in 2026.
Participants must be 23 years or older based on Institutional Review Board (IRB) guidelines.
Minicircle is preparing clinical trial data for publication. Please subscribe to our newsletter or follow us on social media for updates as data becomes available.